VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.
Some of the highlights include:

  • Investments hit record-breaking numbers
  • VC-backed U.S. companies raising 45 mega-rounds (totaling more than $100 million each), up from 35 last quarter
  • 2018 is currently on pace to beat what was an unprecedented 2017, which posted 111 mega-rounds
  • Two of the seven biggest mega-rounds in Q2 were precision medicine companies
    • Allogene Therapeutics – commercializing off-the-shelf CAR-T therapies
    • GRAIL – clinical-stage early detection of cancer
    • Each raising $300 million in oversubscribed financing
  • A review by Silicon Valley Bank found that biopharma Series A investments are exploding, and by mid-year reached $2.6 billion – compared to the full-year total of $2.3 billion in 2017
  • Underscoring robust pre-IPO biopharma valuations, step-ups from Series A to B have seen a two to three-fold increases in the past 18 months
  • Major investments in synthetic biology building blocks, including computational design, CRISPR editing, DNA/RNA synthesis and organism engineering tools, have climbed both in 2017 and 2018
  • 75 VC-backed biopharma unicorns have reached valuations of $1 billion or higher since 2013 – either through acquisition or in the public markets
  • 30 biopharma companies went public already this year – compared to 31 IPOs for all of 2017

2018 is shaping up to be another strong year in healthcare. In the first six months, biopharma exits have created the momentum for strong fundraising and investment.

Source: Silicon Valley Bank
*Most Active New Investments in biopharma defined as Top 60 venture and corporate investors based on new investments in 2016–2017

Underscoring the recent influx of capital over the past two years from the most active investors, every top indication in 1H 2018 other than oncology has already surpassed investment levels for full-year 2016. Waves of new biopharma investment are pushing funding for platform companies to levels similar to oncology and driving a comeback for orphan/rare drugs.

The timely PMWC 2018 Duke conference has several exciting sessions scheduled that focus on the investment sector, new technologies, and a platform for rising startups to share their innovative ideas with the audience via the Showcase Track.

Mike Pellini (Section 32)
Dr. Pellini is Managing Partner of Section 32, a venture fund that invests in companies and inventors that are changing the way humans use technology and the way technology betters humanity. Previously, he served as CEO of Foundation Medicine.
Read his full bio and a recently conducted interview with Mike Pellini.

Arthur Pappas (Pappas Ventures)
Art founded Pappas Capital in 1994, and over the past twenty-four years the firm has managed more than $535 million in capital and invested in more than 70 companies. Art currently serves as a director for Aura Biosciences and OrphoMed, and as a board observer for Amplyx Pharmaceuticals, Balance Therapeutics, Kezar Life Sciences and Real Endpoints. Read his full bio.

Dr. Mickey Kertesz (Karius Dx)
Dr. Kertesz will discuss the technology of his latest company that develops novel NGS infectious disease diagnostics methodology that detects microbial cell-free DNA in plasma from more than a thousand pathogens including bacteria. Read his full bio.

Dr. Robert S. Langer (MIT)
Dr. Langer’s major focus area is Nanotechnology. He is developing new nanoparticles to treat cancer and other diseases. Read his full bio.

Dawn Barry (LunaDNA)
Dawn Barry will dive into blockchain and how they unite personal privacy and control around genomic data with a mechanism for rewards for data sharing in research. Read her full bio.

Showcase Track
The showcase track provides a platform for funded, emerging companies to present their innovative new technologies that intend to disrupt healthcare. Showcases include:

  • AI and Data Sciences
  • Clinical Dx
  • Immunotherapy
  • Genomic profiling
  • Microbial profiling
  • Clinical and Research Tools
  • Non-clinical services
  • Emerging Therapeutics

Apply to present here

Come see these speakers and the Showcase track at
PMWC Duke Sept. 24-25

Interview with Ralph Snyderman from Duke University

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More

Note from Dr. Patrick Conway, President & CEO, Blue Cross and Blue Shield NC to PMWC

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Atul Sharan, Co-founder and CEO, CellMax Life

Q: CellMax has developed non-invasive blood tests based on Circulating tumor cells CTC. How do you see these tests being adopted clinically?

A: Survival rates are greater than 90% for cancers that are detected at an early stage.

Read More

Interview with Wendell Jones from Q² Solutions | EA Genomics

Q: What need is Q² Solutions | EA Genomics addressing?

A: As a leading provider of genomic services in clinical trials and discovery, Q² Solutions | EA Genomics advances science by harnessing technological expertise to drive understanding of the human genome and disease biology to detect the effects of therapies.

Read More

Interview with Ben Solomon from GeneDx

Q: What need is GeneDx addressing?

A: GeneDx was started in 2000 by two NIH scientists with the mission of making genetic testing accessible for patients with rare diseases.

Read More

Interview with Ty Ridenour from RTI International

Q: What need is RTI International addressing?

A: As an independent research institute, RTI is dedicated to improving the human condition. We answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across the social and laboratory sciences, engineering, and international development.

Read More

Interview with Madhuri Hegde, Vice President and Chief Science Officer of PerkinElmer’s Global Laboratory Services

Q: What need is Global Laboratory Services addressing?

A: PerkinElmer Genomics is global (genomics) laboratory service with laboratories in US, India and China, addressing genetic/genomic testing across the globe.

Read More

Interview with Rita R. Colwell from University of Maryland College Park and John Hopkins School of Public Health

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: The research that I am focusing on is understanding the microbiome of the human system and the environment, which means understanding the gut flora and its relationship to health and disease.

Read More

Interview with Dr. Nicholas Dracopoli from Personal Genome Diagnostics

Q: What need is Personal Genome Diagnostics (PGDx) addressing?

A: PGDx is developing standardized, clinical Next Generation Sequencing (NGS) kits to help enable effective treatment decisions for cancer patients.

Read More

Interview with Mohsen Hejrati from Clusterone

Q: What need is Clusterone addressing?

A: AI and machine learning are becoming cornerstone technologies for scientists and engineers, but access to these technologies is still cumbersome.

Read More

VC Investment in Precision Medicine Boomed in Q2 Mega-deals Hitting Record Levels

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Patrick Conway from Blue Cross and Blue Shield of North Carolina

Q: In the past, you served as director of the Center for Medicare and Medicaid Innovation. What are you most proud of accomplishing at CMMI?

A: During my tenure at the Centers for Medicare and Medicaid Services, one of my many roles included serving as the Director of the Center for Medicare and Medicaid Innovation.

Read More
University of Michigan

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

  • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Digital Phenotyping
    • Precision Public Health
    • Pharmacogenomics
    • The Microbiome
    • Rare Disease Diagnosis
    • Digital Health/Health and Wellness
    • Early Days of Life Sequencing
    • Diversity in Precision Medicine
    • Resilience
    • AI and Machine Learning
    • Gene Editing
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Point-of Care Dx Platform
    • FDA Efforts to Accelerate PM
    • Implementation into Health Care Delivery
    • Next Gen. Workforce of PM
    • Immunotherapy
    • Robust Clinical Decision Support Tools
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Neoantigens
    • Emerging Technologies In PM

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

    • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • Digital Phenotyping
      • Precision Public Health
      • Pharmacogenomics
      • The Microbiome
      • Rare Disease Diagnosis
      • Digital Health/Health and Wellness
      • Early Days of Life Sequencing
      • Diversity in Precision Medicine
      • Resilience
      • AI and Machine Learning
      • Gene Editing
      • Large Scale Bio-data Resources
        to Support Drug Development (PPPs)
      • Point-of Care Dx Platform
      • FDA Efforts to Accelerate PM
      • Implementation into Health Care Delivery
      • Next Gen. Workforce of PM
      • Immunotherapy
      • Robust Clinical Decision Support Tools
      • Creating Clinical Value with Liquid Biopsy
        ctDNA, etc.
      • Neoantigens
      • Emerging Technologies In PM
  • Track 2- PMWC 2018 Duke Showcase, will enable 15-minute company presentations on latest novel technologies. Apply to present here.
big data diagnostics session

Clinical Dx Showcase

crispr showcase

Emerging Therapeutics Showcase

NGS Showcase

Genomic Profiling Showcase

AI Showcase Session Image

AI and Data Sciences Showcase

  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 500+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine

[chimpy_lite_form]

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!